Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK12 | Q9NYV4 | 15/20 | 0.58 |
| ▸ | CCNK | O75909 | 14/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.44 |
| ▸ | CCNA2 | P20248 | 9/20 | 0.43 |
| ▸ | CDK2 | P24941 | 9/20 | 0.43 |
| ▸ | CDK7 | P50613 | 9/20 | 0.43 |
| ▸ | CCNH | P51946 | 9/20 | 0.43 |
| ▸ | MNAT1 | P51948 | 9/20 | 0.43 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30464442 | 1.00 | CDK12 (0.58) | CDK12CCNKALDH1A1TP53CDK13 | |
| SCHEMBL25221127 | 0.90 | CDK12 (0.58) | CDK12CCNKCDK13CCNA2CDK2 | |
| SCHEMBL30533853 | 0.87 | CDK12 (0.59) | CDK12CCNKCDK13CCNA2CDK2 | |
| SCHEMBL25219464 | 0.87 | CDK12 (0.59) | CDK12CCNKCDK13CCNA2CDK2 | |
| SCHEMBL25269289 | 0.87 | CCNK (0.53) | CDK12CCNKCDK13CCNA2CDK2 | |
| SCHEMBL30533864 | 0.87 | CCNK (0.53) | CDK12CCNKCDK13CCNA2CDK2 | |
| SCHEMBL25268914 | 0.85 | CDK12 (0.56) | CDK12CCNKCDK13CCNA2CDK2 | |
| SCHEMBL30533789 | 0.85 | CDK12 (0.56) | CDK12CCNKCDK13CCNA2CDK2 | |
| SCHEMBL25222780 | 0.83 | CCNK (0.41) | CDK12CCNKALDH1A1TP53CDK2 | |
| SCHEMBL25222807 | 0.83 | CCNK (0.40) | CDK12CCNKALDH1A1TP53CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORPORATION | 2023-06-29 | — | — | US | claimed |
| WO-2023102184-A1 | BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS | INCYTE CORPORATION (US) | 2023-06-08 | — | — | WO | claimed |
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | INCYTE CORPORATION | 2023-06-29 | — | — | US | disclosed |
| WO-2023102184-A1 | BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS | INCYTE CORPORATION (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023102184-A1 | BICYCLIC AMINE COMPOUNDS AS CDK12 INHIBITORS | INCYTE CORPORATION (US) | 2023-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230203010-A1 | BICYCLIC AMINE CDK12 INHIBITORS | CDK12, CDK1, CDK2 | CDK12 1/4885CCNK 17/4885ALDH1A1 4330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.